• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Yu Ying Choi Alan Abel

    10/17/24 4:30:26 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DWTX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Yu Ying Choi Alan Abel

    (Last) (First) (Middle)
    2 DAI FU STREET,
    TAI PO INDUSTRIAL ESTATE

    (Street)
    NEW TERRITORIES K3

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/07/2024
    3. Issuer Name and Ticker or Trading Symbol
    Dogwood Therapeutics, Inc. [ DWTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Immediately following the effective time of the transaction contemplated by the Share Exchange Agreement by and between the Issuer and Sealbond Limited, a British Virgin Islands corporation, the Reporting Person was appointed to the board of directors of the Issuer.
    No securities are beneficially owned.
    /s/ Yu Ying Choi Alan Abel 10/17/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DWTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DWTX
    Financials

    Live finance-specific insights

    See more
    • Dogwood Therapeutics Announces First Quarter 2025 Financial Results

      - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. "There are no FDA approved treatments to manage the neuropathic pain often resulting from

      5/8/25 9:00:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

      -Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4 2025 - - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward - - Capital raise provides operational runway through Q1 2026 - ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024. "We have made

      3/31/25 3:45:53 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward

      ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, announces that its largest shareholder, CK Life Sciences Int'l., (Holdings), Inc. ("CKLS") has agreed, through its wholly-owned subsidiary, Conjoint Inc. ("Conjoint"), to assign to the Company all outstanding indebtedness under the previously existing $19.5 million Loan Agreement plus accrued interest in exchange for 284.2638 shares of preferred equity of the Company, effective today. "We believe the decision by CKLS to exchange the outst

      3/12/25 8:30:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Dogwood Therapeutics Inc.

      EFFECT - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      6/3/25 12:15:11 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Dogwood Therapeutics Inc.

      S-3 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      5/23/25 5:25:42 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Dogwood Therapeutics Inc.

      10-Q - Dogwood Therapeutics, Inc. (0001818844) (Filer)

      5/9/25 11:28:32 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

      ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, June 12, 2025. Presentation Date: Wednesday, June 11, 2025  Time:  9:15am Easter Time (Track 1) Webcast Link: https://sidoti.zoom.us/webinar/register/WN_C6ACWY1kTXGa0eBkFbVd0w Mr. Duncan will be available for one-on-one meetings. To request a meeting and to register for the conference, click here: htt

      6/3/25 9:15:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics Announces First Quarter 2025 Financial Results

      - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the first quarter ended March 31, 2025. "There are no FDA approved treatments to manage the neuropathic pain often resulting from

      5/8/25 9:00:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

      ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. DWTX Chairman and CEO Greg Duncan stated, "We are pleased that the Company successfully implemented a plan to regain compliance and meet the equity requirement and is continuing to execute that plan going forward." He continued, "The Company has a strong cash positi

      4/11/25 9:15:00 AM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Conjoint Inc.

      3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      3/20/25 8:19:58 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ck Life Sciences Intl (Holdings) Inc

      4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      3/17/25 9:07:18 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Yu Ying Choi Alan Abel

      3 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

      10/17/24 4:30:26 PM ET
      $DWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care